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Abstract
Background: Pathological left ventricular (LV) hypertrophy frequently progresses to dilated heart failure with
suppressed mitochondrial oxidative capacity. Dietary marine ω-3 polyunsaturated fatty acids (ω-3 PUFA) up-regulate
adiponectin and prevent LV dilation in rats subjected to pressure overload. This study 1) assessed the effects of ω-3
PUFA on LV dilation and down-regulation of mitochondrial enzymes in response to pressure overload; and 2)
evaluated the role of adiponectin in mediating the effects of ω-3 PUFA in heart.
Methods: Wild type (WT) and adiponectin-/- mice underwent transverse aortic constriction (TAC) and were fed
standard chow ± ω-3 PUFA for 6 weeks. At 6 weeks, echocardiography was performed to assess LV function, mice
were terminated, and mitochondrial enzyme activities were evaluated.
Results: TAC induced similar pathological LV hypertrophy compared to sham mice in both strains on both diets. In
WT mice TAC increased LV systolic and diastolic volumes and reduced mitochondrial enzyme activities, which were
attenuated by ω-3 PUFA without increasing adiponectin. In contrast, adiponectin-/- mice displayed no increase in
LV end diastolic and systolic volumes or decrease in mitochondrial enzymes with TAC, and did not respond to ω-3
PUFA.
Conclusion: These findings suggest ω-3 PUFA attenuates cardiac pathology in response to pressure overload
independent of an elevation in adiponectin.
Introduction
Consumption of diets enriched in ω-3 polyunsaturated
fatty acids (ω-3 PUFA) from fish (eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA)) is strongly asso-
ciated with a decreased risk of coronary heart disease and
sudden cardiac death [1-3]. Recent evidence suggests that
ω-3 PUFA from fish reduces the incidence of heart failure
[4], and that dietary supplementation with a low dose of
ω-3 PUFA decreases mortality and hospitalization in heart
failure patients [5]. We previously reported that pretreat-
ment with an ω-3 PUFA-enriched diet protects against
ventricular remodeling and dysfunction in a model of
moderate left ventricular (LV) hypertrophy and dysfunc-
tion induced by abdominal aortic banding in rats [6-9].
More severe LV hypertrophy caused by transverse aortic
constriction (TAC) results in chamber dilation and a
decrease in mitochondrial oxidative enzyme activities
[10,11], which is associated with a decrease in the activity
of the fatty acid-activated nuclear receptor peroxisome
proliferator-activated receptor a (PPARa) [12]. The effects
of ω-3 PUFA on the activation of PPARa or cardiac mito-
chondrial oxidative capacity have not been reported under
conditions of severe hypertrophic heart failure. Thus it
remains to be shown if part of the beneficial effect of ω-3
PUFA under conditions of chronic stress is mediated via
maintenance of myocardial oxidative capacity.
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The mechanisms responsible for the protective effects
of ω-3 PUFA are not well-understood. We found that
dietary supplementation with ω-3 PUFA elevated adipo-
nectin concentration in the plasma in a dose-dependent
manner in rats [7], indicating a potential mechanistic
role for adiponectin in mediating the effects of ω-3
PUFA. Adiponectin is an insulin-sensitizing, anti-inflam-
matory hormone that is synthesized in adipocytes and
can exert cardioprotective effects in many species,
including mice [13]. An increase in circulating adiponec-
tin with ω-3 PUFA feeding has been observed in mice
[14,15]. In contrast, elevated circulating adiponectin is a
strong positive predictor of mortality and poor outcome
in heart failure patients [16-19]. Previous reports with
short-term pressure overload (1-3 weeks) induced by
transverse aortic constriction (TAC) showed that adipo-
nectin-deficient (adiponectin-/-) mice displayed con-
centric LV hypertrophy [20], increased mortality [20,21]
and lower ejection fraction compared to wild type (WT)
mice [21]. On the other hand, we recently reported that
adiponectin-/- mice subjected to 6 weeks of TAC dis-
played concentric hypertrophy, preservation of ejection
fraction and chamber size, and no decrease in mito-
chondrial enzyme activities compared to WT mice [22].
At present, it is unclear if the beneficial effects of ω-3
PUFA in preventing the development and progression of
heart failure are dependent upon an increase in circulat-
ing adiponectin.
The goals of the present study were to 1) assess the
effects of ω-3 PUFA on LV chamber expansion and
down-regulation of mitochondrial enzyme activities in
mice subjected to TAC; and 2) evaluate the role of adipo-
nectin in mediating the effects of ω-3 PUFA. Wild type
and adiponectin-/- mice underwent sham surgery or
TAC to elicit LV hypertrophy and heart failure, and were
fed either a standard chow or chow supplemented with
ω-3 PUFA for 6 weeks. The data from the standard
chow-fed adiponectin-/- and WT animals from this study
were previously published [22], and are included here to
serve as controls. The development of heart failure was
evaluated by changes in LV chamber size and up-regula-
tion of the mRNA of fetal genes. To determine if ω-3
PUFA supplementation prevents down-regulation of oxi-
dative capacity the activity of mitochondrial marker
enzymes was measured. The role of adiponectin in med-
iating the effects of ω-3 PUFA was evaluated by measure-
ment of serum adiponectin levels, and by performing a
parallel series of experiments in adiponectin-/- mice.
Methods
Experimental Design
Investigators were blinded to treatment when measure-
ments were performed. The animal protocol was con-
ducted according to the Guideline for the Care and Use
of Laboratory Animals (NIH publication No. 85-23) and
was approved by the University of Maryland School of
Medicine Institutional Animal Care and Use Committee.
The animals were maintained on a 12-hour light-dark
cycle and all procedures were performed between 3 and
6 hours from the start of the light phase. Adiponectin-/-
mice were generated as previously described [23]. It is
important to note that the data from the WT and adi-
ponectin-/- mice without ω-3 PUFA supplementation
were previously reported in a separate publication that
presented the response between the two strains to pres-
sure overload [22]. These studies showed that the adipo-
nectin-/- mice had similar LV hypertrophy and increase
in mRNA markers of heart failure as WT mice; how-
ever, adiponectin deletion prevented the increase in LV
chamber size and the decrease in the activity of mito-
chondrial oxidative enzymes. In the present investigation
we show these data again to allow comparison with the
ω-3 PUFA treated groups. All experimental groups were
contemporary.
Male C57BL/6J (WT) mice and adiponectin-/- mice
(20-25 g) were subjected to TAC with a 27G needle as
previously described [24] or sham surgery (n = 12-15/
group). Two to three days after surgery, the mice were
fed a standard chow (STD) or modified standard chow
containing fish oil composed primarily of DHA and
EPA. The mice were maintained on the diet for 6
weeks. Tail blood pressures were measured at 3-4 weeks
using the tail cuff system. At 6 weeks, LV function was
analyzed by echocardiography and mice were anesthe-
tized with isoflurane, blood was drawn by cardiac punc-
ture into the right ventricle, and the heart was harvested
for biochemical analysis.
Diets
Chows were custom-manufactured (Research Diets Inc.
New Brunswick, NJ). The STD and ω-3 PUFA diets
both derived 70% of total energy from carbohydrate
(40% of total energy from cornstarch, 5% from malto-
dextrin and 25% from sucrose), 20% protein (casein sup-
plemented with L-cystine) and 10% energy from fat. In
the STD diet, fat was made up of 67% lard and 33% soy-
bean oil. The ω-3 PUFA diet derived 2.3% of the total
energy as ω-3 PUFA (3.3% fish oil that was comprised
of 21% EPA and 49% DHA by mass; Ocean Nutrition,
Dartmouth, Nova Scotia, Canada), with the balance of
fat from lard and soybean oil. This fish oil dose corre-
sponds to a human intake of approximately 5.1 g/d of
DHA+EPA (calculated assuming an energy intake of
2000 kcal/d) [7,9].
Echocardiography
LV function was assessed using a Vevo 770 High-Reso-
lution Imaging Systems (Visual Sonics) with a 30-MHz
O’Shea et al. Lipids in Health and Disease 2010, 9:95
http://www.lipidworld.com/content/9/1/95
Page 2 of 9
linear array transducer (model 716). Anesthetized mice
were shaved and placed supine on a warming pad. Two-
dimensional cine loops and guided M-mode frames
were recorded from the parasternal short and long axes.
At the end of the study, all data were analyzed offline
with software resident on the ultrasound system, and
calculations were made to determine LV volumes as
previously described. Ejection fraction was calculated as:
(EDV-ESV)/EDV × 100, where EDV is the end diastolic
volume and ESV is the end systolic volume. Relative
wall thickness was calculated as the sum of the posterior
and anterior wall thickness at end diastole divided by
the end diastolic diameter. Mean wall thickness was
taken as the average of the posterior and anterior wall
thickness at end diastole. All calculations were made
from parasternal short axis measurements.
Metabolic and Biochemical Parameters
Free fatty acids, triglycerides, and glucose (Wako, Rich-
mond, VA) were assessed in the serum using enzymatic
spectrophotometric methods as previously described [7].
Enzyme-linked immunosorbent assays were used to
measure leptin and insulin (both from Alpco Diagnos-
tics, Salem, NH), and adiponectin (Millipore, St. Charles,
MO) levels in the serum. Activities of the mitochondrial
marker enzymes citrate synthase and medium chain
acyl-CoA dehydrogenase (MCAD) were measured spec-
trophotometrically in LV myocardium [7]. Cardiac phos-
pholipid fatty acid composition was assessed in a subset
of sham animals (n = 6/group) on right ventricular
homogenates by gas chromatography with a flame ioni-
zation detector according to a modification of the trans-
esterification method as previously described [25].
For assessment of mRNA expression, frozen LV tissue
was homogenized using a Bullet Blender and RNA was
isolated using the RNeasy Mini Kit following the manu-
facturer’s instructions (Qiagen, Valencia, CA). Real time
RT-PCR was performed using an ABI 7900 Detection
System as previously described [6]. The following genes
were analyzed, using TaqMan gene expression assays
(Applied Biosystems, Foster City, CA): atrial natriuretic
peptide (Nppa, Mm01255747_g1); myosin heavy chain a
(Myh6, Mm00440354_m1); myosin heavy chain b (Myh7,
Mm00600555_m1); MCAD (Acadm, Mm00431611_m1);
citrate synthase (Cs, Mm00466043_m1); uncoupling pro-
tein 3 (Ucp3, Mm01163394_m1), pyruvate dehydrogen-
ase kinase 4 (Pdk4, Mm00443325_m1), and cyclophilin A
(Ppia, Mm02342430_g1). A similar protocol was followed
to isolate RNA from frozen epididymal fat samples, and
RT-PCR was performed for adiponectin (Adipoq,
Mm00456425_m1). mRNA cycle threshold values for
these genes were normalized to the house-keeping gene
cyclophilin A and expressed as fold increase relative to
the standard chow sham group.
Statistical Analysis
Two-way ANOVA with the Bonferonni post hoc adjust-
ment was used to compare the effects of surgery and
diet within the wild type and adiponectin-/- groups
separately and to assess the interaction between surgery
and dietary groups. Statistical comparisons were not
made between wild type and adiponectin-/- groups.
Potential differences in survival were tested using a log
rank test (Sigma Stat 3.5). All data are presented as
means ± SEM. P < 0.05 was accepted as statistically
significant.
RESULTS
Myocardial Phospholipid Composition
Supplementation with ω-3 PUFA significantly altered
the myocardial phospholipid fatty acid composition,
with an increase in DHA and EPA content, and
decreased arachidonic acid content in both WT and adi-
ponectin-/- mice (Table 1). DHA content increased by
~70% with ω-3 PUFA supplementation, and arachidonic
acid decreased by 75%. Palmitic acid was unaffected by
diet, but stearic acid, oleic acid, and linoleic acid levels
were all decreased in animals fed ω-3 PUFA (Table 1).
Left Ventricular Mass, Remodeling, and Contractile
Function
There were no differences among any of the experimen-
tal groups in body mass at baseline or at the end of the
study (Table 2). There was no mortality in sham ani-
mals. In TAC mice survival from the time of assignment
to dietary treatment to the scheduled time of termina-
tion was unaffected by treatment with ω-3 PUFA. Survi-
val in WT TAC mice was 71% and 72% for the STD
Table 1 Right Ventricular Phospholipid Composition in
Sham Mice
WILD TYPE ADIPONECTIN-/-
Fatty Acid (% of
total)
STD ω-3 PUFA STD ω-3 PUFA
Docosahexaenoic
Acid (C22:6n3)
30.5 ± 1.2 50.5 ± 2.2# 30.3 ± 1. 2 51.5 ± 0.9#
Eicosapentaenoic
Acid (C20:5n3)
BQL 1.9 ± 0.2# BQL 1.6 ± 0.2#
Arachidonic Acid
(C20:4n6)
8.3 ± 0.3 1.8 ± 0.1# 9.0 ± 0.4 1.8 ± 0.1#
Palmitic Acid
(C16:0)
14.6 ± 0.5 13.3 ± 0.6 13.9 ± 0.1 13.8 ± 0.4
Stearic Acid
(C18:0)
17.7 ± 0.4 15.6 ± 0.6# 17.5 ± 0.2 15.0 ± 0.2#
Oleic Acid
(C18:1n9)
8.8 ± 0.4 6.6 ± 0.6# 9.0 ± 0.5 5.6 ± 0.4#
Linoleic Acid
(C18:2n6)
16.0 ± 0.7 7.7 ± 0.4# 16.5 ± 0.4 8.1 ± 0.3#
Values are mean ± SEM; n = 6/group. # P < 0.05 vs. standard chow diet. BQL,
below quantifiable limits; TAC, transverse aortic constriction; STD, standard
chow.
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and ω-3 PUFA diets, respectively. Similarly, treatment
with ω-3 PUFA had no significant effect on survival in
adiponectin-/- mice (100% and 82% for STD and ω-3
PUFA, respectively). Tail artery systolic blood pressure
was significantly reduced with TAC in WT mice fed
STD, but not ω-3 PUFA, and was unchanged in adipo-
nectin-/- mice with TAC (Table 2). LV mass expressed
relative to tibia length was increased to a similar extent
in all TAC groups regardless of diet (Figure 1A), indi-
cating LV hypertrophy. Atrial mass was elevated in WT
mice subjected to TAC regardless of diet, and elevated
in adiponectin-/- mice subjected to TAC on STD (Table
2). TAC up-regulated mRNA levels for genes previously
shown to be expressed in heart failure, as seen in a 40-
fold increase in the ratio for MHCb/a in response to
TAC regardless of diet in both strains of mice (Figure
1B). In addition, mRNA for ANF was significantly
increased in all TAC animals compared to sham in WT
and adiponectin-/- mice (Figure 1C).
In WT mice TAC increased LV end diastolic volume
(EDV) and end systolic volume (ESV), which was signifi-
cantly blunted with ω-3 PUFA supplementation (Figure
2). In addition, the prevention in LV dilation with ω-3
PUFA treatment corresponded to an increase in wall
thickness compared to TAC mice fed the STD diet (Fig-
ure 2). On the STD diet TAC resulted in a modest
increase in heart rate, which was not observed in the ω-
3 PUFA group (Table 2). In WT mice ejection fraction
was reduced by TAC and was not affected by ω-3 PUFA
supplementation (Table 2),
In adiponectin-/- mice treatment with ω-3 PUFA had
no significant effects on LV volume in either sham or
TAC groups, however, as we previously reported in a
separate publication, these animals did not develop signif-
icant LV chamber dilation in response to TAC (Figure 2).
There was a main effect of TAC on EDV and ESV (p =
0.046 and p = 0.024, respectively), but the increase was
minor (Figure 2A-B). Furthermore, ejection fraction was
preserved in adiponectin-/- mice subjected to TAC, with
no effect of ω-3 PUFA supplementation (Table 2). Rela-
tive and mean wall thickness in adiponectin-/- mice was
increased by TAC on both diets (Figure 2, Table 2).
Mitochondrial Enzymes
In LV hypertrophy and heart failure, mitochondrial
function and the fatty acid oxidation pathway are
impaired [6,26]. Supplementation with ω-3 PUFA, which
are ligands for PPARa [7], could activate expression of
genes encoding mitochondrial enzymes, thereby redu-
cing the impairment of myocardial energy metabolism
observed with heart failure. In WT mice, there was a
~35% reduction in activities of citrate synthase and
MCAD in LV myocardium with TAC, which was com-
pletely blocked by ω-3 PUFA supplementation. This
effect of ω-3 PUFA was not due to activation of gene
expression, as the mRNA levels of PPARa-regulated
genes was not increased. PDK4 and UCP3 mRNA was
significantly reduced with TAC in STD-fed mice only,
and ω-3 PUFA supplementation reduced PDK4 expres-
sion in sham mice (Table 3). MCAD and citrate
synthase mRNA was reduced with TAC in mice fed
STD chow only (Figure 3D).
In adiponectin-/- mice the activities of MCAD and
citrate synthase were unaffected by surgery or diet
(Figure 3A-B). There were no differences in PDK4 or
UCP3 expression within adiponectin-/- mice, but
MCAD mRNA was reduced by TAC with STD chow
only (Figure 3D). Citrate synthase was decreased in adi-
ponectin-/- mice as a main effect of surgery (p = 0.047)
(Figure 3C).
Metabolic Parameters
In WT mice, total adiponectin was not affected by diet
or surgery, but ω-3 PUFA significantly increased high
molecular weight adiponectin in sham animals and as a
main effect (p = 0.011). However, this effect of ω-3
Table 2 Body and Heart Parameters
WILD TYPE ADIPONECTIN-/-
SHAM TAC SHAM TAC
STD ω-3 PUFA STD ω-3 PUFA STD ω-3 PUFA STD ω-3 PUFA
Baseline body mass (g) 23.2 ± 0.4 22.9 ± 0.3 22.9 ± 0.3 23.6 ± 0.3 21.7 ± 0.4 21.7 ± 0.5 21.5 ± 0.3 22.2 ± 0.5
Terminal body mass (g) 28.0 ± 0.6 27.6 ± 0.5 26.1 ± 0.1 25.8 ± 1.1 26.6 ± 0.8 25.5 ± 0.6 26.5 ± 0.7 26.9 ± 0.6
Tibia length (mm) 19.4 ± 0.2 19.7 ± 0.3 19.2 ± 0.2 19.6 ± 0.2 18.9 ± 0.3 18.5 ± 0.2 18.7 ± 0.2 19.1 ± 0.3
Atrial mass/tibia length (mg·cm-1) 0.73 ± 0.07 0.50 ± 0.04 1.60 ± 0.29* 1.16 ± 0.13* 0.55 ± 0.06 0.76 ± 0.09 1.00 ± 0.09* 0.93 ± 0.13
Mean Diastolic Wall Thickness (μm) 76.5 ± 2.8 74.7 ± 3.7 80.9 ± 4.6 100.4 ± 3.6*# 79.8 ± 3.8 84.0 ± 3.6 114.8 ± 5.8* 109.1 ± 6.9*
Ejection Fraction (%) 50.9 ± 2.04 48.8 ± 3.5 25.9 ± 3.6* 22.9 ± 3.3* 51.5 ± 5.1 61.0 ± 3.0 46.5 ± 3.6 51.8 ± 3.5
Systolic Blood Pressure (mm Hg) 112 ± 3 105 ± 3 99 ± 2* 100 ± 3 120 ± 3 116 ± 3 112 ± 3 117 ± 3
Heart Rate (bpm) 597 ± 14 581 ± 15 637 ± 11* 616 ± 10 604 ± 13 577 ± 11 619 ± 11 610 ± 14
Values are mean ± SEM; n = 12-15/group. *P < 0.05 vs. sham; # P < 0.05 vs. standard chow diet. TAC, transverse aortic constriction; STD, standard chow. Heart
rate data were obtained in conscious mice during tail cuff blood pressure measurements.
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Figure 1 LV mass/tibia length (A), the mRNA expression of the
ratio of myosin heavy chain (MHC) b to MHCa (B), and the
mRNA expression of atrial natriuretic peptide (ANF) expressed
as a fraction of the sham wild type standard chow diet. Values
are mean ± SEM; n = 12-15/group. *P < 0.05 vs. sham.
Figure 2 Echocardiographic assessment of left ventricular end
diastolic volume (A), end systolic volume (B), and relative wall
thickness (C). Values are mean ± SEM; n = 12-15/group. *P < 0.05
vs. sham; # P < 0.05 vs. standard chow diet.
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Table 3 Metabolic Parameters
WILD TYPE ADIPONECTIN-/-
SHAM TAC SHAM TAC
STD ω-3 PUFA STD ω-3 PUFA STD ω-3 PUFA STD ω-3 PUFA
Serum Adiponectin (μg·ml-1) 7.94 ± 1.23 8.74 ± 1.35 7.72 ± 1.27 7.48 ± 1.23 1.70 ± 0.12 1.56 ± 0.10 1.50 ± 0.10 1.49 ± 0.10
Serum HMW Adiponectin (μg·ml-1) 0.55 ± 0.03 0.78 ± 0.08# 0.63 ± 0.05 0.73 ± 0.08 0.18 ± 0.03 0.18 ± 0.03 0.19 ± 0.02 0.19 ± 0.03
Adiponectin mRNA in Epididymal Fat 1.00 ± 0.17 1.10 ± 0.10 1.04 ± 0.14 1.18 ± 0.27 0 0 0 0
PDK4 mRNA in LV 1.00 ± 0.35 0.30 ± 0.03# 0.29 ± 0.04* 0.29 ± 0.04 0.27 ± 0.03 0.40 ± 0.11 0.37 ± 0.08 0.48 ± 0.14
UCP3 mRNA in LV 1.00 ± 0.14 0.88 ± 0.13 0.39 ± 0.07* 0.47 ± 0.12 0.89 ± 0.12 0.96 ± 0.11 0.49 ± 0.09 0.59 ± 0.10
Serum Glucose (mM) 12.7 ± 0.6 11.6 ± 0.8 12.6 ± 1.0 11.4 ± 0.9 13.0 ± 0.9 12.7 ± 0.7 11.7 ± 0.4 13.1 ± 1.1
Serum FFA (mM) 0.69 ± 0.05 0.55 ± 0.04 0.76 ± 0.14 0.55 ± 0.07 0.82 ± 0.08 0.47 ± 0.06 0.61 ± 0.07 0.52 ± 0.08
Serum Insulin (ng·ml-1) 0.66 ± 0.16 0.90 ± 0.20 0.66 ± 0.16 0.48 ± 0.10 0.84 ± 0.23 0.54 ± 0.11 0.60 ± 0.10 0.34 ± 0.10
Serum Leptin (ng·ml-1) 2.56 ± 0.51 2.80 ± 0.70 1.62 ± 0.37 1.18 ± 0.28* 3.83 ± 1.50 2.28 ± 0.82 1.85 ± 0.43 0.78 ± 0.14
Serum Triglycerides (mg·ml-1) 0.26 ± 0.05 0.25 ± 0.06 0.25 ± 0.07 0.28 ± 0.06 0.40 ± 0.09 0.23 ± 0.08 0.30 ± 0.04 0.25 ± 0.06
Values are mean ± SEM; n = 12-15/group. *P < 0.05 vs. sham, #P < 0.05 vs. standard chow diet. HMW, high molecular weight; PDK4, pyruvate dehydrogenase
kinase 4; UCP3, uncoupling protein 3; FFA, free fatty acids; LV, left ventricle; TAC, transverse aortic constriction; STD, standard chow. mRNA data are expressed as
fold change relative to the mean of the wild type sham standard chow group.
Figure 3 Myocardial activity of citrate synthase (A) and medium chain acyl-CoA dehydrogenase (MCAD) (B), and the mRNA expression
of MCAD (C) and citrate synthase (D). Values are mean ± SEM; n = 12-15/group. *P < 0.05 vs. sham; # P < 0.05 vs. standard chow diet.
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PUFA was modest in the TAC group (~16%). Total
serum adiponectin and high molecular weight adiponec-
tin did not change with diet or surgery in adiponectin-/-
mice (Table 3). The mRNA level of adiponectin was
undetectable in the epididymal fat pads of all adiponec-
tin-/- mice and unaltered by diet or surgery in WT
mice (Table 3).
Serum glucose, free fatty acids, triglycerides, and insu-
lin were not different among any of the groups in either
strain (Table 3). Serum leptin was not different among
adiponectin-/- groups, but was significantly reduced in
the WT TAC compared to sham ω-3 PUFA-fed mice.
Discussion
The main novel finding of the present study is that
treatment with ω-3 PUFA can prevent down-regulation
in the activity of mitochondrial enzymes under condi-
tions of severe pressure overload despite no diminution
in LV hypertrophy or the classic up-regulation of the
mRNA for fetal genes. Importantly, the maintenance in
mitochondrial enzyme activity corresponded with
attenuation of LV chamber expansion. Lastly, ω-3 PUFA
supplementation did not increase adiponectin in TAC
animals, suggesting that the protective effects of ω-3
PUFA occur independent of up-regulation of circulating
adiponectin.
In the present study we observed a protective effect of
ω-3 PUFA in WT mice, with an attenuation of the
increase in end diastolic and systolic volumes with TAC
and maintenance of cardiac mitochondrial enzyme func-
tion. In our previous studies in rats with a similar dose
of ω-3 PUFA we observed a large increase (~70%) in
total circulating adiponectin [6,7,9]. In the current study
we did not see the expected increase in total serum adi-
ponectin in WT mice with ω-3 PUFA supplementation.
However, we did observe a small non-significant 16%
increase in high molecular weight adiponectin in the
serum. The lack of effect of ω-3 PUFA on total adipo-
nectin could be due to regulation of adiponectin forma-
tion and secretion, thereby changing the amount of the
various molecular weight isoforms. In addition, there
could be differences between species. Most reports with
fish oil supplementation indicate an up-regulation of the
expression and secretion of adiponectin in rats [6-8] and
humans [27]; however, there are reports where adipo-
nectin is unaffected by fish oil supplementation in rats
and mice [28,29]. In a study in mice fed a diet substi-
tuted with various DHA analogs, serum adiponectin was
either reduced or unchanged [29]. Clearly, additional
research is needed to address the specific role of ω-3
PUFA in adiponectin regulation.
Long chain fatty acids, including ω-3 PUFA are endo-
genous ligands for PPARa [30], which may prevent the
decline in PPARa activation and mitochondrial function
that is commonly observed in advanced heart failure
[31]. In the present investigation we show preservation
of mitochondrial enzyme activities with dietary ω-3
PUFA supplementation after TAC. However, the mRNA
for genes encoding the mitochondrial proteins citrate
synthase, MCAD, PDK4 and UCP3 does not closely mir-
ror the changes observed in activities of citrate synthase
and MCAD (Table 3 and Figure 3). The mRNA for all
four genes decreased with TAC in WT mice fed STD,
but was not increased by ω-3 PUFA feeding. This dis-
crepancy between gene expression and enzyme activity
has been previously reported in other models of heart
failure and pathological cardiac hypertrophy [10,32].
Thus, it does not appear that ω-3 PUFA preferentially
activate PPARa under physiological conditions to confer
cardioprotection in the setting of heart failure. ω-3
PUFA supplementation may be maintaining mitochon-
drial enzyme activity via changes in mitochondrial mem-
brane composition, as we observed an increase in DHA
and decrease in arachidonic acid, which may favorably
alter mitochondrial function and structure, as previously
suggested [33].
The effects of ω-3 PUFA on structural and metabolic
LV remodeling were markedly different compared to
STD-fed controls in each strain. The inherent differ-
ences in the response of the LV to pressure overload
between the two strains of mice have been detailed in
our previous report [22]. We observed the expected
chamber dilation and reduction in ejection fraction after
TAC in WT mice, but severe concentric hypertrophy
with maintenance of ejection fraction in adiponectin-/-
mice. In the present investigation we found that WT
mice experienced LV dilation that was attenuated by ω-
3 PUFA supplementation, but there was no effect of ω-3
PUFA on LV remodeling in adiponectin-/- mice. In
addition, the WT mice fed STD displayed a decrease in
the activity of mitochondrial oxidative enzymes that
classically occurs in advanced LV hypertrophy and heart
failure [34], but the activities were maintained with ω-3
PUFA supplementation. In the adiponectin-/- mice,
there was no effect of TAC or dietary ω-3 PUFA on
mitochondrial enzyme activities. Taken together, it
appears that the beneficial effects of ω-3 PUFA on the
heart are not dependent on an increase in adiponectin.
The effects of ω-3 PUFA supplementation on phos-
pholipid composition in cardiac tissue have been well-
documented in humans [35], rats [7,9], dogs [36], and
mice [37]. Notably, mice have higher DHA levels in car-
diac phospholipids without dietary ω-3 PUFA (~30% of
total phospholipid fatty acid; Table 1) [37] compared to
humans and dogs (~1%) [35,36] or rats (~8%) [7,9]. In
the present study ω-3 PUFA supplementation increased
the DHA content of membranes in mice to approxi-
mately 50% of total fatty acids, while a low level of
O’Shea et al. Lipids in Health and Disease 2010, 9:95
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supplementation increases DHA content to approxi-
mately 2-3% in humans [35]. The pronounced difference
in membrane DHA content between humans and mice
limits the application of these results from mice to
human disease.
In summary, treatment with ω-3 PUFA prevented LV
chamber expansion and down-regulation of the activity
of mitochondrial enzymes under conditions of severe
pressure overload despite no diminution in LV hypertro-
phy or mRNA markers of heart failure. ω-3 PUFA sup-
plementation maintained cardiac mitochondrial enzyme
activity, which corresponded with prevention of LV
chamber expansion. These effects occurred despite no
ω-3 PUFA-induced increase in adiponectin, suggesting
that the protective effects of ω-3 PUFA occur indepen-
dent of up-regulation of circulating adiponectin.
Conflict of interest
The authors declare that they have no competing interests.
Authors’ contributions
KMO designed the study, performed the physiological and biochemical
measurements, analyzed the data and wrote the manuscript. DJC assisted in
the design of the study and performed all animal surgeries. RJK performed
biochemical analyses. PAH performed biochemical analyses. BL performed
extensive preliminary studies and assisted with the study design. K W
assisted in the design of the study, data analysis, and writing the
manuscript. CDR performed the phospholipid analysis, and assisted in data
analysis and writing the manuscript. WCS conceived and designed the
study, analyzed the data and wrote the manuscript. All authors read and
approved the final manuscript
Acknowledgements
We acknowledge Kim Carpenter and Alexander Mamunes for the help with
the terminal surgeries and animal husbandry, and Dr. Willem Kop for
assistance with the statistical analyses. Supported by NIH grants HL074237,
HL091307, and HL101434.
Author details
1Division of Cardiology and Department of Medicine, University of Maryland,
Baltimore, MD, USA. 2Whitaker Cardiovascular Institute, Boston University
School of Medicine, Boston, MA, USA. 3Department of Nutrition and
Montreal Heart Institute, Université de Montréal, Montreal, Canada.
Received: 4 August 2010 Accepted: 6 September 2010
Published: 6 September 2010
References
1. Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3
fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
2. Lavie CJ, Milani RV, Mehra MR, Ventura HO: Omega-3 polyunsaturated
fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009, 54:585-594.
3. Leaf A, Kang JX, Xiao YF, Billman GE: Clinical prevention of sudden cardiac
death by n-3 polyunsaturated fatty acids and mechanism of prevention
of arrhythmias by n-3 fish oils. Circulation 2003, 107:2646-2652.
4. Mozaffarian D, Bryson CL, Lemaitre RN, Burke GL, Siscovick DS: Fish intake
and risk of incident heart failure. J Am Coll Cardiol 2005, 45:2015-2021.
5. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al:
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart
failure (the GISSI-HF trial): a randomised, double-blind, placebo-
controlled trial. Lancet 2008, 372:1223-1230.
6. Duda MK, O’Shea KM, Lei B, Barrows BR, Azimzadeh AM, McElfresh TE, et al:
Dietary supplementation with omega-3 PUFA increases adiponectin and
attenuates ventricular remodeling and dysfunction with pressure
overload. Cardiovasc Res 2007, 76:303-310.
7. Duda MK, O’Shea KM, Tintinu A, Xu W, Khairallah RJ, Barrows BR, et al: Fish
oil, but not flaxseed oil, decreases inflammation and prevents pressure
overload-induced cardiac dysfunction. Cardiovasc Res 2009, 81:319-327.
8. Duda MK, O’Shea KM, Stanley WC: omega-3 polyunsaturated fatty acid
supplementation for the treatment of heart failure: mechanisms and
clinical potential. Cardiovasc Res 2009, 84:33-41.
9. Shah KB, Duda MK, O’shea KM, Sparagna GC, Chess DJ, Khairallah RJ, et al:
The cardioprotective effects of fish oil during pressure overload are
blocked by high fat intake: role of cardiac phospholipid remodeling.
Hypertension 2009, 54:605-611.
10. Chess DJ, Khairallah RJ, O’shea KM, Xu W, Stanley WC: A High Fat Diet
Increases Adiposity but Maintains Mitochondrial Oxidative Enzymes
without Affecting Development of Heart Failure with Pressure Overload.
Am J Physiol Heart Circ Physiol 2009, 297:1585-1593.
11. Garnier A, Fortin D, Delomenie C, Momken I, Veksler V, Ventura-Clapier R:
Depressed mitochondrial transcription factors and oxidative capacity in
rat failing cardiac and skeletal muscles. J Physiol 2003, 551:491-501.
12. Huss JM, Kelly DP: Nuclear receptor signaling and cardiac energetics. Circ
Res 2004, 95:568-578.
13. Hopkins TA, Ouchi N, Shibata R, Walsh K: Adiponectin actions in the
cardiovascular system. Cardiovasc Res 2007, 74:11-18.
14. Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, et al:
Fish oil regulates adiponectin secretion by a peroxisome proliferator-
activated receptor-gamma-dependent mechanism in mice. Diabetes
2006, 55:924-928.
15. Kuda O, Jelenik T, Jilkova Z, Flachs P, Rossmeisl M, Hensler M, et al: n-3
fatty acids and rosiglitazone improve insulin sensitivity through additive
stimulatory effects on muscle glycogen synthesis in mice fed a high-fat
diet. Diabetologia 2009, 52:941-951.
16. Ingelsson E, Riserus U, Berne C, Frystyk J, Flyvbjerg A, Axelsson T, et al:
Adiponectin and risk of congestive heart failure. JAMA 2006,
295:1772-1774, %19.
17. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, et al: Circulating
adiponectin concentrations in patients with congestive heart failure.
Heart 2006, 92:1420-1424.
18. Frankel DS, Vasan RS, D’Agostino RB Sr, Benjamin EJ, Levy D, Wang TJ, et al:
Resistin, adiponectin, and risk of heart failure the Framingham offspring
study. J Am Coll Cardiol 2009, 53:754-762.
19. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, et al:
Plasma adiponectin, body mass index, and mortality in patients with
chronic heart failure. Circulation 2005, 112:1756-1762.
20. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, et al:
Adiponectin-mediated modulation of hypertrophic signals in the heart.
Nat Med 2004, 10:1384-1389.
21. Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I, et al:
Exacerbation of heart failure in adiponectin-deficient mice due to
impaired regulation of AMPK and glucose metabolism. Cardiovasc Res
2005, 67:705-713.
22. O’Shea KM, Chess DJ, Khairallah RJ, Rastogi S, Hecker PA, Sabbah HN, et al:
Effects of adiponectin deficiency on structural and metabolic
remodeling in mice subjected to pressure overload. Am J Physiol Heart
Circ Physiol 2010, 298:H1639-H1645.
23. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H,
et al: Diet-induced insulin resistance in mice lacking adiponectin/
ACRP30. Nat Med 2002, 8:731-737.
24. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE: Minimally
invasive aortic banding in mice: effects of altered cardiomyocyte insulin
signaling during pressure overload. Am J Physiol Heart Circ Physiol 2003,
285:H1261-H1269.
25. Lepage G, Roy CC: Direct transesterification of all classes of lipids in a
one-step reaction. J Lipid Res 1986, 27:114-120.
26. Duda MK, O’Shea KM, Lei B, Barrows BR, Azimzadeh AM, McElfresh TE, et al:
Low carbohydrate/high fat diet attenuates pressure overload induced
ventricular remodeling and dysfunction. J Card Fail 2007, 14:327-335.
27. Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, et al:
Increased adiponectin secretion by highly purified eicosapentaenoic
acid in rodent models of obesity and human obese subjects. Arterioscler
Thromb Vasc Biol 2007, 27:1918-1925.
28. de Mattos AB, Pinto MJ, Oliveira C, Biz C, Ribeiro EB, do Nascimento CM,
et al: Dietary fish oil did not prevent sleep deprived rats from a
O’Shea et al. Lipids in Health and Disease 2010, 9:95
http://www.lipidworld.com/content/9/1/95
Page 8 of 9
reduction in adipose tissue adiponectin gene expression. Lipids Health
Dis 2008, 7(43):43.
29. Rossmeisl M, Jelenik T, Jilkova Z, Slamova K, Kus V, Hensler M, et al:
Prevention and reversal of obesity and glucose intolerance in mice by
DHA derivatives. Obesity (Silver Spring) 2009, 17:1023-1031.
30. Barger PM, Kelly DP: PPAR signaling in the control of cardiac energy
metabolism. Trends Cardiovasc Med 2000, 10:238-245.
31. Lei B, Lionetti V, Young ME, Chandler MP, D’Agostino C, Kang E, et al:
Paradoxical downregulation of the glucose oxidation pathway despite
enhanced flux in severe heart failure. J Mol Cell Cardiol 2004, 36:567-576.
32. Morgan EE, Chandler MP, Young ME, McElfresh TA, Kung TA, Rennison JH,
et al: Dissociation between gene and protein expression of metabolic
enzymes in a rodent model of heart failure. Eur J Heart Fail 2006,
8:687-693.
33. O’Shea KM, Khairallah RJ, Sparagna GC, Xu W, Hecker PA, Robillard-Frayne I,
et al: Dietary omega-3 fatty acids alter cardiac mitochondrial
phospholipid composition and delay Ca2+-induced permeability
transition. J Mol Cell Cardiol 2009, 47:819-827.
34. Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism
in the normal and failing heart. Physiol Rev 2005, 85:1093-1129.
35. Harris WS, Sands SA, Windsor SL, Ali HA, Stevens TL, Magalski A, et al:
Omega-3 fatty acids in cardiac biopsies from heart transplantation
patients: correlation with erythrocytes and response to
supplementation. Circulation 2004, 110:1645-1649.
36. Billman GE, Nishijima Y, Belevych AE, Terentyev D, Xu Y, Haizlip KM, et al:
Effects of dietary omega-3 fatty acids on ventricular function in dogs
with healed myocardial infarctions: in vivo and in vitro studies. Am J
Physiol Heart Circ Physiol 2010, 298:H1219-H1228.
37. Hussein N, Fedorova I, Moriguchi T, Hamazaki K, Kim HY, Hoshiba J, et al:
Artificial rearing of infant mice leads to n-3 fatty acid deficiency in
cardiac, neural and peripheral tissues. Lipids 2009, 44:685-702.
doi:10.1186/1476-511X-9-95
Cite this article as: O’Shea et al.: ω-3 Polyunsaturated fatty acids
prevent pressure overload-induced ventricular dilation and decrease in
mitochondrial enzymes despite no change in adiponectin. Lipids in
Health and Disease 2010 9:95.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
O’Shea et al. Lipids in Health and Disease 2010, 9:95
http://www.lipidworld.com/content/9/1/95
Page 9 of 9
